XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Total revenues $ 22,120,000 $ 15,443,000
Cost of sales (5,963,000) (3,770,000)
Gross profit 16,157,000 11,673,000
Operating expenses:    
Selling, general and administrative 13,398,000 8,164,000
Research and development 658,000 592,000
Total operating expenses 14,056,000 8,756,000
Income from operations 2,101,000 2,917,000
Other (expense) income:    
Interest expense, net (1,792,000) (513,000)
Equity in losses of unconsolidated entities (2,886,000) (1,319,000)
Investment gain (loss) from Eton Pharmaceuticals 139,000 (2,835,000)
Gain on forgiveness of PPP loan 1,967,000
Total other expense, net (4,539,000) (2,700,000)
(Loss) income before income taxes (2,438,000) 217,000
Income taxes
Net (loss) income attributable to common stockholders $ (2,438,000) $ 217,000
Basic net (loss) income per share of common stock $ (0.09) $ 0.01
Diluted net (loss) income per share of common stock $ (0.09) $ 0.01
Weighted average number of shares of common stock outstanding, basic 27,226,819 26,019,255
Weighted average number of shares of common stock outstanding, diluted 27,226,819 27,480,622
Product Sales, Net [Member]    
Revenues:    
Total revenues $ 20,340,000 $ 14,948,000
Other Revenues [Member]    
Revenues:    
Total revenues $ 1,780,000 $ 495,000